Figure 1.
Sequentialpostvaccination antispike protein IgG levels. Changes in antispike protein IgG levels are shown in patients with CLL (A) or MBL (B) and treatment history (C). An antispike antibody level >50 AU/mL is classified as a positive response and an antispike antibody level ≥1000 AU/mL is classified as a strong positive response. Red bars in panel C indicate the median antispike antibody level in each group. An antispike antibody level of 0 could not be displayed in this figure. Although Australia had low COVID-19 case numbers, consensus guidelines developed at the beginning of the pandemic recommended deferral of CLL therapy where possible during COVID-19 outbreaks.33,34 Hence, the number of patients on therapy (panel C box 4) is relatively low. pre-vacc, prevaccine.

Sequentialpostvaccination antispike protein IgG levels. Changes in antispike protein IgG levels are shown in patients with CLL (A) or MBL (B) and treatment history (C). An antispike antibody level >50 AU/mL is classified as a positive response and an antispike antibody level ≥1000 AU/mL is classified as a strong positive response. Red bars in panel C indicate the median antispike antibody level in each group. An antispike antibody level of 0 could not be displayed in this figure. Although Australia had low COVID-19 case numbers, consensus guidelines developed at the beginning of the pandemic recommended deferral of CLL therapy where possible during COVID-19 outbreaks.33,34 Hence, the number of patients on therapy (panel C box 4) is relatively low. pre-vacc, prevaccine.

Close Modal
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal